Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Lenalidomide (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2016 Status changed from suspended to discontinued.
- 22 Aug 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 04 Jan 2011 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.